Analysis of the Prognostic Role of Epigenetic Biomarkers in Relation to the Motor Decline in Park… (NCT05384522) | Clinical Trial Compass
UnknownNot Applicable
Analysis of the Prognostic Role of Epigenetic Biomarkers in Relation to the Motor Decline in Parkinson's Disease
103 participantsStarted 2024-05-30
Plain-language summary
BioGenParkinson is an observational, prospective cohort study evaluating biomarkers of Parkinson's Disease (PD) progression in community-dwelling subjects aged 65 years or more, consecutively referring to INRCA outpatient clinic of the Neurology Unit. Selected patients will undergo clinical and laboratory evaluations at the baseline, and will be followed up after 6 and 12 months. The biological evaluation will include the determination of i) routine biological parameters ii) advanced biomarkers such as epigenetic analysis of DNA methylation, genetic analysis on multiple loci associated with PD progression and specific proteins associated with motor and non-motor decline. After obtaining all data, multiple statistical analysis will be performed to evaluate the most accurate prognostic biomarkers of PD progression at this stage of disease.
Who can participate
Age range
65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* PD at Hoehn and Yahr stage ≤3
* MMSE test ≥24 score
Exclusion Criteria:
* MMSE score \< 24
* Severe cardiovascular diseases (including congestive heart failure NYHA=4, acute coronary syndrome, stroke)
* History of traumatic brain injury, previous deep brain surgery
* Current substance or alcohol abuse
* Reduced life expectancy less than six months
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study is focused on observing epigenetic biomarkers and their relationship to motor decline in Parkinson's disease — does that mean it involves no experimental treatment, and if so, what would my participation actually look like day-to-day?
2Since the recruitment status for this trial is listed as unknown, can you find out whether it is still actively enrolling patients before we consider it as an option?
3This trial is measuring whether epigenetic biomarkers can predict how quickly motor symptoms progress — how might the information gathered benefit my care now versus only contributing to future research for other patients?
4Because this appears to be an observational study rather than a treatment trial, would participating in it prevent me from also pursuing other treatment options or clinical trials at the same time?
5Given that this study is in Parkinson's disease specifically, are there standard-of-care approaches to monitoring and managing my motor symptoms that we should be prioritizing alongside or instead of considering this trial?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Prognostic role of epigenetic biomarkers with respect to the advancing of PD motor decline
Timeframe: Baseline and 12 months later
Trial details
NCT IDNCT05384522
SponsorIstituto Nazionale di Ricovero e Cura per Anziani